Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
62.09(c) 61.61(c) 61.92(c) 63.22(c) 62.84(c) Last
9 025 456 8 305 175 9 595 949 13 512 667 9 520 905 Volume
+0.13% -0.77% +0.50% +2.10% -0.60% Change
More quotes
Financials (USD)
Sales 2020 42 144 M - -
Net income 2020 1 779 M - -
Net Debt 2020 35 216 M - -
P/E ratio 2020 97,4x
Yield 2020 2,85%
Sales 2021 45 890 M - -
Net income 2021 8 181 M - -
Net Debt 2021 29 610 M - -
P/E ratio 2021 15,1x
Yield 2021 3,04%
Capitalization 142 B 142 B -
EV / Sales 2020 4,21x
EV / Sales 2021 3,74x
Nbr of Employees 30 000
Free-Float 77,2%
More Financials
Company
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are... 
Sector
Pharmaceuticals
Calendar
01/28Earnings Release
More about the company
Notations Surperformance© of Bristol-Myers Squibb Company
Trading Rating : Investor Rating :
More Ratings
All news about BRISTOL-MYERS SQUIBB COMPANY
11/25BRISTOL MYERS SQUIBB : Receives European Commission Approval for Opdivo as Secon..
AQ
11/25SUTRO BIOPHARMA : to Host a Virtual KOL Event to Provide Clinical Update on Anti..
AQ
11/24BRISTOL MYERS SQUIBB : Gets EU Approval of Opdivo in Esophageal Cancer
DJ
11/24BRISTOL MYERS SQUIBB : Receives European Commission Approval for Opdivo (nivolum..
BU
11/23BRISTOL MYERS SQUIBB : Schrodinger, Bristol Myers Squibb to Collaborate on Drugs
DJ
11/23BRISTOL MYERS SQUIBB : Schrödinger Announces a Multi-Target Drug Discovery, Deve..
BU
11/18BRISTOL MYERS SQUIBB : Foundation and National Medical Fellowships Launch $100 M..
AQ
11/18BRISTOL MYERS SQUIBB : Completes Acquisition of MyoKardia, Strengthening Company..
AQ
11/17BRISTOL MYERS SQUIBB CO : Other Events, Financial Statements and Exhibits (form ..
AQ
11/17BRISTOL MYERS SQUIBB : Provides Regulatory Update on Lisocabtagene Maraleucel
AQ
11/17BRISTOL MYERS SQUIBB : Completes Acquisition of MyoKardia, Strengthening Company..
BU
11/17BRISTOL MYERS SQUIBB : Foundation and National Medical Fellowships Launch $100 M..
BU
11/16Berkshire Hathaway Invests in Drugmakers Seeking Covid-19 Vaccine -- 2nd Upda..
DJ
11/16Berkshire Hathaway Invests in Drugmakers Seeking Covid-19 Vaccine -- Update
DJ
11/16Berkshire Hathaway Invests in Drugmakers Seeking Covid-19 Vaccine
DJ
More news
News in other languages on BRISTOL-MYERS SQUIBB COMPANY
11/17BERKSHIRE HATHAWAY INVESTIT DANS LE : Merck, bms, pfizer...
11/17Alors, on rebat les cartes ?
11/17EN DIRECT DES MARCHES : Dassault Systèmes, Iliad, Vallourec, CGG, Trigano, BBVA,..
11/06BRISTOL MYERS : une approbation de la Commission européenne
11/05Zuversicht beim US-Pharmakonzern Bristol-Myers steigt
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 74,22 $
Last Close Price 62,84 $
Spread / Highest target 40,0%
Spread / Average Target 18,1%
Spread / Lowest Target 1,85%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Senior Vice President
Vicki L. Sato Lead Independent Director
Gerald L. Storch Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-2.10%142 003
JOHNSON & JOHNSON-1.50%378 744
ROCHE HOLDING AG-4.28%281 946
PFIZER INC.-1.59%203 437
MERCK & CO., INC.-11.89%202 757
NOVARTIS AG-12.66%200 273